It is interesting to note that CTLA-4 inhibitors are more likely to cause de novo irAEs, while PD-1/PD-L1 inhibitors are relatively more likely to cause the exacerbation of autoimmune diseases. The gene discussed is CD274; the disease is autoimmune disease.